Thelansis

  Pfizer Inc. announced the FDA approval of HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing the frequency of bleeding episodes. This approval covers both adult and pediatric patients aged 12 years and older who have hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. This milestone underscores Pfizer's commitment to providing innovative therapies for patients with bleeding disorders. Publish Date: 14-10-2024   Source: Pfizer Inc. Hemophilia is a severe hereditary hemorrhagic disorder, with significant types of hemophilia A (classic hemophilia or factor VIII deficiency) and hemophilia B (also known as Christmas disease or factor IX deficiency). The disorder is inherited and is characterized by a deficiency of clotting factors in the blood. Hemophilia C is a rare condition caused by a deficiency of clotting factor ...

 Hemophilia A, an x-linked genetic disorder, is characterized by a factor VIII deficiency. Factor VIII primarily originates from the liver and is secreted into the bloodstream inactive, forming a complex with the von Willebrand factor. Other tissues, including the endothelium, also contribute to factor VIII production. In contrast, factor IX is exclusively produced by the liver. Among the enduring complications of hemophilia, chronic hemarthroses are frequently encountered. In cases of intra-articular bleeding, spontaneous resolution can occur or be facilitated by treatment during acute episodes. Numerous patients will encounter recurrent bleeding incidents, developing one or more target joints that often cause pain and limit their daily activities. These target joints are commonly found in the knee, elbow, and ankle. Over time, chronic synovitis and persistent hemarthroses can culminate in degenerative joint ailments, osteoarthritis, and the formation of osteophytes. ·  ...

 Hemophilia A is an x-linked genetic disorder characterized by factor VIII deficiency. The liver is the predominant source of factor VIII, secreted and circulated in the bloodstream in an inactive form in a complex with von Willebrand factor. Several other tissues produce factor VIII, including the endothelium. Factor IX is produced entirely by the liver. Chronic hemarthroses are one of the most common long-term complications of hemophilia. Intra-articular bleeding may resolve on its own or with treatment in an acute case. However, many patients will experience recurrent bleeding and develop single or multiple target joints that are often painful and restrict their daily activity. Common sites are the knee, elbow, and ankle. Over time, chronic synovitis and chronic hemarthroses can result in degenerative joint disease, osteoarthritis, and osteophyte formation. ·        In the United States, most people with hemophilia are diagnosed very young; Hemoph...

Hemophilia A is an x-linked genetic disorder characterized by the deficiency of factor VIII. the liver is the predominant source of factor VIII, which is then secreted and circulated in the bloodstream in an inactive form in a complex with von Willebrand factor. Several other tissues produce factor VIII, including the endothelium. Factor IX is produced entirely by the liver. Chronic hemarthroses are one of the most common long-term complications of hemophilia. Intra-articular bleeding may resolve on its own or with treatment in an acute case. However, many patients will experience recurrent bleeding and develop single or multiple target joints that are often painful and restrict their daily activity. Common sites are the knee, elbow, and ankle. Over time, chronic synovitis and chronic hemarthroses can result in degenerative joint disease, osteoarthritis, and osteophyte formation. In the United States, most people with hemophilia are diagnosed at a very young age, Hemophilia A affects 1...